Design and SAR of new substituted purines bearing aryl groups at N9 position as HIV-1 Tat–TAR interaction inhibitors
Authors:
- Chunlei ZhangCZChunlei Zhang
- Dekai YuanDYDekai Yuan
- Ming YangMYMing Yang
- 1 September 2008
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 16 (17) , 8178-8186
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Discoveries of Tat-TAR Interaction Inhibitors for HIV-1Current Drug Targets - Infectious Disorders, 2005
- Antiretroviral therapies for treatment-experienced patients: current status and research challengesAIDS, 2005
- Antiviral drugs in current clinical useJournal of Clinical Virology, 2004
- Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA PanelClinical Infectious Diseases, 2003
- The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targetsExpert Review of Anti-infective Therapy, 2003
- Antiretroviral Treatment for Adult HIV Infection in 2002JAMA, 2002
- New developments in anti-HIV chemotherapyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2002
- Biochemical and Functional Interactions between HIV-1 Tat Protein and TAR RNAArchives of Biochemistry and Biophysics, 1999
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entryNature Medicine, 1998
- Determination of the Minimal Amount of Tat Activity Required for Human Immunodeficiency Virus Type 1 ReplicationVirology, 1997